Project Grant K23DA060993

Award Date 6/15/24
Completion Date 5/31/29
Dollars Obligated $190K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $197,748 to The Regents of the University of California, San Francisco to develop and pilot an enhanced low-dose buprenorphine initiation (LDI) program. The goal is to improve treatment outcomes for individuals with opioid use disorder, particularly those using fentanyl, by overcoming barriers to successful buprenorphine initiation and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $196,236 to The Washington University to conduct research focused on disparities in the prescription and effectiveness of medications to treat opioid use disorder (OUD) during pregnancy. The key objectives of the 5-year project are to: 1) evaluate how race and racial segregation are associated with the use of buprenorphine and methadone as well...
This $680,046 Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), aims to study how social functioning and engagement behaviors change during opioid use disorder (OUD) treatment. The 5-year study will combine established ecological momentary assessment (EMA) methods with a smartwatch-based application (SocialBit) to assess both subjective self-reports and objective measurements of social behaviors, social...
This $385,000 Project Grant award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to advance integrated treatment for co-occurring opioid use disorder (OUD) and alcohol use disorder (AUD) in real-world settings. The key objectives are to: Assess the effectiveness of integrated treatment approaches, including first-line medications and glucagon-like peptide-1 receptor agonists (GLP-1 RAs), for patients with co-occurring OUD...
This Project Grant award, with a total funding amount of $379,792, was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The award aims to develop and pilot test the "Patient Reported Outcome Measures to Individualize Treatment and Improve Retention" (RETAIN) program intervention package. This program will capture patient-reported outcome measures (PROMs) in Federally-Qualified Health Center (FQHC)-based opioid use...
This Project Grant award of $184,613 from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) supports the training of a Chicana epidemiologist to develop a multi-component intervention to address the co-occurring epidemics of HIV, hepatitis C (HCV), and opioid use among Latino persons who inject drugs living along the Texas-Mexico border. The 5-year project, titled "PROYECTO VIDA," will optimize four intervention protocols: peer navigation...
This Project Grant award of $815,779 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), will fund a study to comprehensively characterize the care pathways utilized by patients with substance use disorder (SUD) within a large integrated healthcare system. The study aims to: (1) apply multi-state Markov models to analyze care transitions across the spectrum of SUD treatment, (2) generate data-driven insights to improve SUD care...
This federal Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) totaling $945,397 provides funding to the Magee-Womens Research Institute and Foundation, with a sub-award to the University of Pittsburgh, to adapt and evaluate a collaborative care model (CCM) for treating pregnant persons with opioid use disorder (OUD) in low-resource obstetric settings. The key objectives are to: 1) adapt the CCM for rural and low-resource...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $208,575.00 to Dr. R. Kathryn McHugh at McLean Hospital to expand her mentorship of early-career investigators in patient-oriented research (POR) on substance use disorders. The award will enable Dr. McHugh to dedicate more time to mentoring current and new mentees, as well as broaden her own POR program. This includes extending existing...
This $360,720 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support a randomized controlled trial examining the use of extended-release injectable buprenorphine for the treatment of opioid use disorder (OUD) in individuals who use high-potency synthetic opioids. The primary objectives are to: 1) compare abstinence and relapse rates between injectable buprenorphine and sublingual buprenorphine/naloxone...

USING CLINICAL DECISION SUPPORT TO PROVIDE SOCIAL RISK-INFORMED CARE FOR OPIOID USE DISORDER IN THE EMERGENCY DEPARTMENT - PROJECT SUMMARY/ABSTRACT DR. MELANIE MOLINA IS AN ASSISTANT CLINICAL PROFESSOR OF EMERGENCY MEDICINE AT THE UNIVERSITY OF CALIFORNIA, SAN FRANCISCO (UCSF) WHOSE LONG-TERM GOAL IS TO BECOME AN INDEPENDENT INVESTIGATOR STUDYING HOW TO LEVERAGE HEALTH INFORMATION TECHNOLOGY TO IMPROVE CARE FOR PATIENTS EXPERIENCING SOCIAL DISADVANTAGE. TO ACHIEVE THIS GOAL, SHE WILL DEVELOP CRITICAL SKILLS IN CLINICAL INFORMATICS, HUMAN-CENTERED DESIGN, AND IMPLEMENTATION SCIENCE BY: 1) COMPLETING FORMAL COURSEWORK IN SQL AND CLARITY DATA MODEL FUNDAMENTALS, HUMAN-CENTERED DESIGN, AND DESIGNING INDIVIDUAL-LEVEL IMPLEMENTATION STRATEGIES, 2) ATTENDING STRUCTURED DIDACTICS, RESEARCH GROUP MEETINGS, JOURNAL CLUBS, AND WORKS-IN-PROGRESS SESSIONS, AND 3) PERFORMING GOAL- DIRECTED TRAINING ACTIVITIES IN DATA QUERY, RETRIEVAL, AND ANALYSIS, CONTEXTUAL INQUIRY AND FOCUS GROUP DESIGN, AND INTERVENTION IMPLEMENTATION AND PILOT DATA COLLECTION. THE RESEARCH INFRASTRUCTURE AND RESOURCES AT UCSF, INCLUDING THE CENTER FOR CLINICAL INFORMATICS AND IMPROVEMENT RESEARCH AND THE CLINICAL AND TRANSLATIONAL SCIENCE INSTITUTE, WILL PROVIDE DR. MOLINA WITH ALL THE SUPPORT NECESSARY TO COMPLETE THE WORK PROPOSED IN HER CAREER DEVELOPMENT APPLICATION. DR. MOLINA HAS ASSEMBLED AN EXCEPTIONAL MENTORSHIP TEAM: DR. LAURA GOTTLIEB (PRIMARY MENTOR) IS A PROFESSOR OF FAMILY AND COMMUNITY MEDICINE WITH EXPERTISE IN SOCIAL DETERMINANTS OF HEALTH, DR. JULIA ADLER-MILSTEIN (CO-MENTOR) IS A PROFESSOR OF MEDICINE AND CHIEF OF THE DIVISION OF CLINICAL INFORMATICS WITH EXPERTISE IN ELECTRONIC HEALTH RECORD (EHR) DATA, AND DR. COURTNEY LYLES (CO-MENTOR) IS A PROFESSOR IN THE DEPARTMENT OF PUBLIC HEALTH SCIENCES AT UC DAVIS WITH EXPERTISE IN HUMAN-CENTERED DESIGN AND IMPLEMENTATION SCIENCE METHODOLOGIES. THE OVERARCHING GOAL OF THIS PROPOSAL IS TO INTEGRATE PATIENT SOCIAL RISK INFORMATION INTO AN EXISTING EHR- BASED CLINICAL DECISION SUPPORT (CDS) TOOL TO FACILITATE ED-INITIATED, SOCIAL RISK-INFORMED OPIOID USE DISORDER (OUD) MEDICATION TREATMENT AND ULTIMATELY IMPROVE TREATMENT ADHERENCE AND FOLLOW UP. DR. MOLINA WILL START BY EXTRACTING METADATA FROM EPIC'S REPORTING DATABASE CAPTURING WHETHER DISCRETE SOCIAL RISK DATA WERE DOCUMENTED AND/OR REVIEWED BY ED CLINICIANS FOR OUD-RELATED ED ENCOUNTERS (AIM 1). USING INSIGHTS FROM AIM 1-IN ADDITION TO A HUMAN-CENTERED DESIGN APPROACH WITH SEMI-STRUCTURED QUALITATIVE INTERVIEWS OF KEY ED STAFF AND PATIENT STAKEHOLDERS-SHE WILL INTEGRATE PATIENT SOCIAL RISKS INTO AN EXISTING CDS TOOL FOR OUD TREATMENT, CREATING A PROTOTYPE THAT PROVIDES SOCIAL CARE-ENHANCED OUD TREATMENT RECOMMENDATIONS (AIM 2). SHE WILL THEN EVALUATE THE FEASIBILITY AND ACCEPTABILITY OF THE SOCIAL CARE-ENHANCED CDS TOOL AT THE UCSF ED AS AN INTERVENTION TO INCREASE TREATMENT ADHERENCE AND FOLLOW UP USING A MIXED-METHODS, BEFORE-AFTER APPROACH (AIM 3). THIS PROPOSAL FULFILLS THE NATIONAL INSTITUTE OF DRUG ABUSE RESEARCH PRIORITY OF UNDERSTANDING HOW TO ADAPT EXISTING SERVICES INTO MORE PATIENT-CENTERED MODELS OF CARE.

Posted 6/7/24, 12:00 AM